BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q4 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,415 | -12.8% | 20,880 | +2.5% | 0.00% | -25.0% |
| Q2 2023 | $1,622 | -26.0% | 20,362 | -33.4% | 0.00% | -33.3% |
| Q1 2023 | $2,193 | -28.4% | 30,585 | -17.4% | 0.01% | -25.0% |
| Q4 2022 | $3,064 | -99.9% | 37,041 | +96.9% | 0.01% | -50.0% |
| Q3 2022 | $5,341,000 | +3.2% | 18,809 | +22.3% | 0.02% | +6.7% |
| Q2 2022 | $5,177,000 | +0.4% | 15,381 | +32.6% | 0.02% | +15.4% |
| Q1 2022 | $5,156,000 | +143.1% | 11,601 | +170.5% | 0.01% | +160.0% |
| Q4 2021 | $2,121,000 | +26.6% | 4,289 | +24.0% | 0.01% | 0.0% |
| Q3 2021 | $1,675,000 | -2.6% | 3,458 | -11.7% | 0.01% | 0.0% |
| Q2 2021 | $1,719,000 | +4.8% | 3,917 | -25.4% | 0.01% | -16.7% |
| Q4 2020 | $1,640,000 | -63.7% | 5,250 | -71.9% | 0.01% | -70.0% |
| Q3 2020 | $4,518,000 | +316.4% | 18,700 | +345.2% | 0.02% | +185.7% |
| Q2 2020 | $1,085,000 | +24.1% | 4,200 | -6.7% | 0.01% | 0.0% |
| Q1 2020 | $874,000 | -18.7% | 4,500 | -10.0% | 0.01% | 0.0% |
| Q4 2019 | $1,075,000 | -66.6% | 5,000 | -69.3% | 0.01% | -65.0% |
| Q3 2019 | $3,218,000 | -48.3% | 16,310 | -45.9% | 0.02% | -35.5% |
| Q2 2019 | $6,227,000 | +135.7% | 30,170 | +118.5% | 0.03% | +93.8% |
| Q1 2019 | $2,642,000 | +8.6% | 13,810 | -19.8% | 0.02% | 0.0% |
| Q4 2018 | $2,433,000 | -7.9% | 17,210 | +24.6% | 0.02% | 0.0% |
| Q3 2018 | $2,642,000 | +26.7% | 13,810 | -2.5% | 0.02% | +14.3% |
| Q2 2018 | $2,085,000 | -0.2% | 14,170 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $2,089,000 | +1.1% | 14,170 | -18.8% | 0.01% | -12.5% |
| Q4 2017 | $2,066,000 | 0.0% | 17,460 | 0.0% | 0.02% | 0.0% |
| Q3 2017 | $2,066,000 | +0.9% | 17,460 | 0.0% | 0.02% | 0.0% |
| Q2 2017 | $2,048,000 | +16.1% | 17,460 | 0.0% | 0.02% | 0.0% |
| Q1 2017 | $1,764,000 | -7.6% | 17,460 | -0.4% | 0.02% | -27.3% |
| Q2 2016 | $1,910,000 | +24.9% | 17,530 | +9.6% | 0.02% | +22.2% |
| Q1 2016 | $1,529,000 | -11.3% | 16,000 | -15.3% | 0.02% | -10.0% |
| Q4 2015 | $1,724,000 | -0.3% | 18,900 | +1.1% | 0.02% | -4.8% |
| Q3 2015 | $1,729,000 | -37.7% | 18,700 | -33.7% | 0.02% | -36.4% |
| Q2 2015 | $2,775,000 | +0.5% | 28,184 | +2.4% | 0.03% | -2.9% |
| Q1 2015 | $2,761,000 | +11.9% | 27,534 | +4.2% | 0.03% | +9.7% |
| Q4 2014 | $2,468,000 | – | 26,425 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |